Hundreds of millions of doses of Russia-made Sputnik V Covid-19 vaccine, which reportedly showed a 97.6% efficacy, will come with the label "Made in China", said a report by CNN.

Over the past month, companies in China have made agreements to manufacture more than 260 million doses of Russia's Sputnik V vaccine, which has been approved for use in more than 60 countries including a large number of developing nations such as Mexico, India and Argentina.

This deals between China and Russia shows an aligned vaccine goals which assist in neglection of developing countries, like India, Mexico and Argentina, by their traditional Western partners (like the US and Canada) who have been accused of hoarding shots.

According to a research by Duke University, Countries such as Canada, the UK and New Zealand, have bought enough vaccines to cover their population more than 3-times over, while the vast majority of countries have barely got doses for half their citizens, including some of the nations worst hit by Covid-19. [check this screenshot link if your browser/antivirus blocking this Duke University's research website]

In recent months, Russian disinformation efforts have tried to undermine confidence in US and UK vaccines, such as those made by Pfizer and AstraZeneca, according to Judyth Twigg, professor of political science at Virginia Commonwealth University, according to Judyth Twigg, professor of political science at Virginia Commonwealth University. China with its state-run media is also exaggerating reports of deaths from US and European-made vaccines.

Bobo Lo, an expert on China-Russia relations and former deputy head of mission at Australia's embassy in Moscow, said both Russia and China saw an opportunity for geopolitical gains in the pandemic, winning favor and influence for their autocratic systems.

The Duke University research further states --
Several middle-income countries, including India, also have robust vaccine development programs and are putting forward vaccine candidates, though these are not as far along in the process as the leading candidates from high-income countries. If any of the candidates from middle-income countries achieve regulatory approval, the landscape will likely shift significantly.

According to the models by Duke University predict that there will not be enough vaccines to cover the world's population until 2023 or 2024. Manufacturing capacity can be expanded with targeted investment but only to an extent and it will remain a rate limiter.

Post a Comment

Previous Post Next Post
Like this content? Sign up for our daily newsletter to get latest updates.